Neurogastrx, Inc.
Neurogastrx is a privately held, late clinical-stage biopharmaceutical company focused on discovering and developing transformative therapies for gastrointestinal disorders affecting the enteric nervous system. The company aims to address serious GI conditions with limited treatment options, leveraging scientific innovation and a dedicated management team.
Industries
Nr. of Employees
small (1-50)
Patents
Products
NG101 (oral peripherally‑acting D2 receptor antagonist)
Oral, peripherally restricted small‑molecule dopamine D2 receptor antagonist developed for reduction of nausea and vomiting associated with GLP‑1 agonists and for treatment of gastroparesis; completed proof‑of‑concept study and a Phase 2 trial.
Fexuprazan (investigational P‑CAB for erosive esophagitis)
Investigational potassium‑competitive acid blocker being developed for treatment of erosive esophagitis; intended to block proton pumps and suppress gastric acid secretion.
NG101 (oral peripherally‑acting D2 receptor antagonist)
Oral, peripherally restricted small‑molecule dopamine D2 receptor antagonist developed for reduction of nausea and vomiting associated with GLP‑1 agonists and for treatment of gastroparesis; completed proof‑of‑concept study and a Phase 2 trial.
Fexuprazan (investigational P‑CAB for erosive esophagitis)
Investigational potassium‑competitive acid blocker being developed for treatment of erosive esophagitis; intended to block proton pumps and suppress gastric acid secretion.
Expertise Areas
- Clinical trial management
- Gastrointestinal drug development
- Regulatory strategy and submissions
- Small‑molecule drug discovery and translational development
Key Technologies
- Dopamine D2 receptor antagonists
- Potassium‑competitive acid blocker (P‑CAB) approach
- Peripherally‑restricted small‑molecule design
- Oral small‑molecule salt formulations
News & Updates
Neurogastrx announced positive topline results from a study of NG101 showing significant reduction of nausea and vomiting caused by GLP-1 agonist medication. The study demonstrated a 40% reduction in nausea incidence and a 56% reduction in vomiting frequency, with no new safety concerns.
Neurogastrx raised $45 million in Series A financing to develop NG101 for gastroparesis, aiming to bring it through proof of concept.
Neurogastrx announced positive topline results from a study of NG101 showing significant reduction of nausea and vomiting caused by GLP-1 agonist medication. The study demonstrated a 40% reduction in nausea incidence and a 56% reduction in vomiting frequency, with no new safety concerns.
Neurogastrx raised $45 million in Series A financing to develop NG101 for gastroparesis, aiming to bring it through proof of concept.